
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics Inc. has demonstrated promising clinical outcomes for its product candidate RLY-2608, particularly in specific patient populations with kinase mutations, achieving an overall response rate (ORR) of 67% and a median progression-free survival (mPFS) of 11.4 months. The FDA's recent approval of Truqap, which similarly targets advanced breast cancer, underscores the growing recognition and efficacy of therapies that address key biomarker alterations in oncology, further validating Relay’s strategic focus on precision medicine. As the company advances its innovative Dynamo platform and expands its pipeline, the combination of improved clinical data and regulatory support positions Relay Therapeutics favorably for future growth and impact in the biopharmaceutical landscape.
Bears say
Relay Therapeutics is facing significant financial headwinds, with projections indicating a full-year 2025 net loss of $2.15 per share, a slight improvement over the previous year's estimate of $2.36 per share. The company is exposed to multiple risks, including negative clinical data, setbacks in development timelines, and possible failures in obtaining regulatory approvals, which could detrimentally impact its pipeline of drug candidates. Additionally, the competitive landscape poses challenges, with the potential for lower-than-expected commercial success and medium- to long-term dilution risks further complicating the company's financial outlook.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares